Last reviewed · How we verify
Lanitop (METILDIGOXIN)
Lanitop (generic name: METILDIGOXIN) is a metildigoxin drug. It is currently in Phase 2 development.
Lanitop works by blocking the sodium-potassium pump in the heart, which helps regulate the balance of sodium and potassium ions.
Lanitop, also known as metildigoxin, is a small molecule drug that targets the sodium/potassium-transporting ATPase subunit alpha-1. It is a member of the metildigoxin class and works by inhibiting the sodium-potassium pump, leading to increased levels of potassium and decreased levels of sodium in the heart. However, due to the lack of available information, its commercial status, approved indications, half-life, bioavailability, and generic manufacturers are unknown. Lanitop's safety considerations and efficacy are also not well-documented. Further research is needed to fully understand this medication.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | METILDIGOXIN |
|---|---|
| Drug class | metildigoxin |
| Target | Sodium/potassium-transporting ATPase subunit alpha-1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Think of the sodium-potassium pump like a gatekeeper that controls the flow of sodium and potassium ions in and out of the heart cells. When Lanitop blocks this pump, it allows more potassium to enter the cells and less sodium to leave, which can help slow down the heart rate and improve its function.
Approved indications
Common side effects
- Cardiac failure
- N-terminal prohormone brain natriuretic peptide increased
- Wound haemorrhage
- Toxic neuropathy
- Bradycardia
- Refractory anaemia with an excess of blasts
- Aortic stenosis
- Congestive cardiomyopathy
- Cerebral infarction
- Embolic stroke
- Dyspnoea
- General physical health deterioration
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lanitop CI brief — competitive landscape report
- Lanitop updates RSS · CI watch RSS
Frequently asked questions about Lanitop
What is Lanitop?
How does Lanitop work?
What is the generic name of Lanitop?
What drug class is Lanitop in?
What development phase is Lanitop in?
What are the side effects of Lanitop?
What does Lanitop target?
Related
- Drug class: All metildigoxin drugs
- Target: All drugs targeting Sodium/potassium-transporting ATPase subunit alpha-1
- Therapeutic area: All drugs in Cardiovascular
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing